{"id":1018646,"date":"2026-11-09T07:35:21","date_gmt":"2026-11-09T12:35:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/"},"modified":"2026-11-09T07:35:21","modified_gmt":"2026-11-09T12:35:21","slug":"zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/","title":{"rendered":"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference"},"content":{"rendered":"
\n

WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management\u2019s presentation at the Jefferies London Global Healthcare Conference on Monday, November 16, 2026, at 5:00 p.m. GMT.<\/p>\n

A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations<\/a> section of the Zenas BioPharma website<\/a>.<\/p>\n

\n About Zenas BioPharma<\/strong>
\n
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas\u2019 lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and Fc\u03b3RIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib\u2019s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas\u2019 earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA\/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and Fc\u03b3RIIb monoclonal antibody. For more information about Zenas BioPharma, please visit\u00a0https:\/\/zenasbio.com\/<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>.<\/p>\n

\n Zenas BioPharma Forward-Looking Statements<\/strong>\u00a0<\/p>\n

This press release contains \u201cforward-looking statements.\u201d In some cases, forward-looking statements can be identified by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward looking statements include, but are not limited to, statements regarding our product candidates, including the therapeutic potential of our product candidates; and the potential commercial attributes and opportunities for our product candidates. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company\u2019s actual results, performance or achievements to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty of clinical development; the Company\u2019s ability to obtain regulatory approval to commercialize its product candidates; and other risks and uncertainties described in the section \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented from time to time by our subsequent filings with the Securities and Exchange Commission (the \u201cSEC\u201d), as well as other information we file with the SEC. Because forward-looking statements are inherently subject to risks and uncertainties, these forward-looking statements should not be relied upon as guarantees of future events. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.\u00a0<\/p>\n

The Zenas BioPharma word mark, logo mark, and the \u201clightning bolt\u201d design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors:<\/strong>
\n
Argot Partners
Zenas@argotpartners.com<\/a><\/p>\n

\n Media:<\/strong>
\n
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management\u2019s presentation at the Jefferies London Global Healthcare Conference on Monday, November 16, 2026, at 5:00 p.m. GMT. A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced … <\/p>\n

Continue reading “Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018646","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nZenas BioPharma to Present at the Jefferies London Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management\u2019s presentation at the Jefferies London Global Healthcare Conference on Monday, November 16, 2026, at 5:00 p.m. GMT. A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced … Continue reading "Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T12:35:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference\",\"datePublished\":\"2026-11-09T12:35:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/\"},\"wordCount\":692,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/\",\"name\":\"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=\",\"datePublished\":\"2026-11-09T12:35:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management\u2019s presentation at the Jefferies London Global Healthcare Conference on Monday, November 16, 2026, at 5:00 p.m. GMT. A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced … Continue reading \"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T12:35:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference","datePublished":"2026-11-09T12:35:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/"},"wordCount":692,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/","name":"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=","datePublished":"2026-11-09T12:35:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjYzNiM3OTQ0ODQ5IzIyMDc3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-jefferies-london-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018646"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018646\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}